Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | JS009 |
Synonyms | |
Therapy Description |
Limited information is currently available on JS009, a putative CD112R antibody (Apr 2023). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
JS009 | JS-009|JS 009|TAB009|TAB-009|TAB 009 | Limited information is currently available on JS009, a putative CD112R antibody (Apr 2023). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT05650203 | Phase I | JS006 + JS009 + Toripalimab-tpzi JS009 | A Study of JS009 Monotherapy and JS009 as a Triple Combination Therapy in Patients With Advanced Malignancies | Withdrawn | 0 |